Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is focusing on the development and commercialization of innovative treatments of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Strategically, Santhera focuses on RaxoneŽ (INN: idebenone) in mutliple indications.

Products & Pipeline

Santhera's first product RaxoneŽ has received European marketing authorization in Leber's Hereditary Optic Neuropathy. The compound is also being developed in Duchenne Muscular Dystrophy, and primary Progressive Multiple Sclerosis. Omigapil, a second compound, is in clinical development to treat Congenital Muscular Dystrophy.

Clinical Development Programs

Currently, the NIH are investigating the safety and efficacy of RaxoneŽ in a Phase II trial (IPPoMS) as potential therapy of primary progressive Multiple Sclerosis. Also at the NIH, a Phase I study (CALLISTO) is being conducted to investigate the omigapil in pediatric and adolescent patients suffering from Congenital Muscular Dystrophy.

Latest News

January 27, 2016
Santhera Reports Preliminary Key Financial Figures for 2015
January 18, 2016
Santhera Signs Distribution and Supply Agreement for RaxoneŽ with Ewopharma Covering Eastern Europe and The Baltics
December 02, 2015
Santhera Completed Share Placement and Raised CHF 54.8 Million